Compound Profile

Atractylenolide II

Atractylodes sesquiterpene lactone with anti inflammatory pathway activity via NF κB.

Use extra caution Review medications, pregnancy status, chronic conditions, and clinician guidance before use. Details

Last reviewed: 1 source citedReport a correctionProfile-wide ·C Limited
Atractylenolide II monograph visual
Generated profile category visual

At a glance

From this profile's structured data
Evidence
Grade C
Safety
Safety evidence: review-level evidence is primarily in vitro and animal-based and is sparse.
Profile context
NF-κB, MAPK
Next steps

Continue reading

Quick stats

Evidence level
Limited evidence
Typical onset
Varies by prep
Safety rating
Use extra caution: Interaction risk
Best for
NF κB, MAPK

Botanical Context

Source botanicals and comparison guides related to Atractylenolide II.

Safety

Safety & Cautions

High caution

Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.

  • Interaction-AwareMedication or interaction context is explicitly noted.
  • Liver-SensitiveLiver-related caution language appears in the profile.
  • Pregnancy/Breastfeeding CautionPregnancy or breastfeeding caution language is present.
Safety evidence
review-level evidence is primarily in vitro and animal-based and is sparse
Who should avoid this?
No specific evidence-backed contraindication is documented for this profile. This is not the same as established safety.
Talk to a professional if
you use relevant medications, you are pregnant or breastfeeding, surgery is planned or recent, you have a condition named in this safety summary.

Human dose-response, pregnancy, breastfeeding, liver, kidney, surgery, and medication-interaction safety remain insufficient.

Evidence Summary

Profile-wide ·C Limited

Evidence lens

Read as directional context, not settled clinical proof.

LimitedLimited evidence

Human clinical evidence: Not the primary signal

Mechanistic / preclinical: Mechanism mappedInflammatory Signaling Modulation · NF KB Modulation · Inflammatory

Research maturity: Theoretical / mechanistic researchMechanistic or unresolved evidence is kept separate from established human outcomes.

Safety boundary: Safety note availableReview medications, pregnancy status, chronic conditions, and clinician guidance before use.

This profile cites 1 human study.

Evidence Strength

Confidence estimate based on the design quality and consistency of published clinical trials.

Limited evidence

Atractylenolide II has a limited evidence rating.

General wellnessGeneral wellness
Citation density
0.5
Sources
1
Effects
2
Research recency
Mixed recency
Evidence Grade

Grade C: Limited Evidence

Evaluation of methodological rigor, population reach, and evidence alignment.

Design Match
Narrative review
Risk of Bias
High
Consistency
Not assessed
Strongest recorded design is a narrative review, drawn from 1 recorded study, none of which measured an outcome in people.
How evidence grades work

Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.

Strong
Multiple RCTs, consistent direction, adequate effect size
Moderate
Some RCTs or consistent observational data in humans
Preliminary / Mixed
Animal or in-vitro only, or conflicting human data
Traditional / Theoretical
Traditional use only; no controlled human trials
Clinical Study Summaries (1)0 human evidence sources · 0 human trials · Participant totals not consistently reported · Consistency not yet classifiable

What the evidence actually shows

This table contains 1 structured source, including 0 human evidence sources; 0 are human trials.

StudyDesignNDoseDurationPopulationOutcomeResult & magnitudeSource

Atractylenolides (I, II, and III): a review of their pharmacology and pharmacokinetics

Deng M et al. · Arch Pharm Res · 2021

Background
Narrative review

Summarizes selected literature without the full prespecified search and selection methods of a systematic review.

PubMed

How Atractylenolide II Works

Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.

Mechanism Pathway — How Atractylenolide II Works

How Atractylenolide II WorksAtractylenolide II acts on biological target pathways via anti inflammatory, leading to nf κb.Atractylenolide IIBiological TargetBiological pathwayAnti InflammatoryNf κBObservable outcomeNF KB InhibitionParallel pathway
CompoundTarget / ReceptorMechanismEffect / Outcome

Dosing

No standardized dose
standardized extract or essential oil free preparation when oral use is intended
Mechanisms & biological pathways

Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.

  • Inflammatory Signaling Modulation
  • NF KB Modulation
  • Inflammatory

Guides that use Atractylenolide II

Continue exploring

Related research paths

Compare & Sourcing

Compare side-by-side tradeoffs or verify active marker guidelines.

Free safety checklist

Get the Atractylenolide II evidence notes

Occasional research updates, safety context, and product-quality checks for supplement decisions.

We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.

Safety first · Harm reduction

This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.

Learn how we evaluate confidence, safety, and intensity on the methodology page.

Editorial Review

Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.

Editorial Standards →

Help improve this profile

Was this useful for your research?

These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.

Was this evidence summary clear?

Did you find what you were researching?